Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

Fig. 2

Endpoint results. Brain Atrophy endpoints (per-protocol population). Panel a shows percentage brain volume change (PBVC) as measured by SIENA comparing baseline and 24-month Magnetic Resonance Imaging (MRI). P value was calculated using a generalized linear model (GLM) adjusted for the baseline Multiple Sclerosis Functional Composite (MSFC). I bars indicate standard deviation. Panel b shows Brain Parenchymal Fraction (BPF) change comparing baseline and 24-month MRI. P value was calculated using GLM adjusted for the baseline Multiple Sclerosis Functional Composite (MSFC). I bars indicate standard deviation. Three-month confirmed disability progression endpoint (intention-to-treat population). Panel c shows cumulative probability of clinical disability progression as defined by an increase in the Expanded Disability Status Scale that was confirmed after 3 months of follow-up, in a time-to-event analysis. P value calculated with the use of the log-rank test. Cox proportional regression was used for calculation hazard ratio using baseline Multiple Sclerosis Functional Composite (MSFC), sex, phenotype and baseline progression as covariates

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us